CGRP enhanced the resistance of two CALCRL- and RAMP1-expressing human AML cell lines to araC and daunorubicin, and this effect was counteracted both by shRNA-mediated downregulation of CALCRL and by receptor inhibition through the truncated peptide, CGRP(8−37), or the small molecule olcegepant [74] (Figure 2). This evidence concerns the gene RAMP1 and acute myeloid leukemia.